Appili Therapeutics and the Future of Biodefense
Appili Therapeutics Inc. has recently made significant strides in its biodefense initiatives, particularly with its innovative vaccine candidate, ATI-1701. This novel vaccine aims to safeguard against tularemia, a serious infectious disease caused by the bacterium Francisella tularensis.
Promising Developments for ATI-1701
During the upcoming IDWeek 2024 conference, Appili will present vital updates on the ATI-1701 vaccine, focusing on newly gathered efficacy data. Research indicates that a single dose of ATI-1701 offers complete protection to animal models against lethal tularemia, lasting over a year following vaccination.
Understanding Tularemia and Its Risks
Tularemia, categorized as a bioterrorism agent, poses a significant threat due to its high infectivity—it's over a thousand times more infectious than anthrax. Consequently, developing effective medical countermeasures is a primary concern globally. With no approved vaccine available in the main markets, ATI-1701 holds immense promise as a preventive measure.
Funding and Support for Research
Appili has successfully acquired a $14 million funding commitment from the United States Air Force Academy, collaborating with the Defense Threat Reduction Agency. The financial backing aims to propel the ATI-1701 program forward, with plans for an Investigational New Drug (IND) submission to the U.S. FDA scheduled for 2025.
Expert Insights from Appili Team
Dr. Gary Nabors, Appili's Chief Development Officer, expressed optimism regarding the progress made in vaccine manufacturing and the results from studies showing long-term immunity. The government funding serves as a strong basis for accelerating the vaccine's development and potentially brings ATI-1701 closer to the market.
Presentation Highlights at IDWeek 2024
Appili's participation in IDWeek 2024 is a key opportunity to share their findings with a broader audience of infectious disease professionals. The outline of their presentation includes:
- Poster Title: Toward the clinical development of ATI-1701, a genetically defined live attenuated tularemia vaccine
- Date: October 17, 2024
- Time: 12:15 PM PT / 3:15 PM ET
- Location: Los Angeles Convention Center, Hall J & K
About Appili Therapeutics
Appili Therapeutics is committed to combating infectious diseases through innovative biopharmaceutical solutions. Their mission involves identifying urgent health issues that require novel therapies. Currently, their portfolio includes various anti-infectives, demonstrating Appili's strategic approach to reducing the impact of serious infections worldwide.
Contact Information for Appili
For inquiries, interested parties are encouraged to reach out regarding potential collaborations or further information about ATI-1701 or other initiatives. Contact:
Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Email: info@appilitherapeutics.com
Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Email: Info@AppiliTherapeutics.com
Frequently Asked Questions
What is ATI-1701?
ATI-1701 is a live-attenuated vaccine candidate developed by Appili Therapeutics to prevent tularemia.
Why is tularemia considered a significant concern?
Tularemia is highly infectious and can potentially be used as a biological weapon, making effective treatments and vaccines a priority.
What are the latest advancements regarding ATI-1701?
Recent studies show that ATI-1701 can provide long-lasting protection, with a single dose ensuring immunity for over a year.
How is Appili funded for its research?
Appili has secured funding from organizations like the U.S. Air Force Academy to advance the development of ATI-1701.
What is IDWeek 2024?
IDWeek 2024 is a conference that gathers professionals in infectious diseases to share the latest scientific findings and advancements.